MIT Spin-Off Evaluates Vascular Drug Delivery With $500,000 In VC Funds
This article was originally published in The Gray Sheet
Executive Summary
Pervasis Therapeutics will rely in part on seed money from two Boston venture capital firms to help commercialize a vascular drug delivery device that would promote tissue healing